Live news related to MAAT PHARMA stock (FR0012634822): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on MAAT PHARMA mainly cover M&A activity et share price moves. The stock trades at €1,04 on Euronext Paris, down 2,62% at the last update. This page lists the articles published on MAAT PHARMA stock to track the share price, company announcements and any item likely to influence market perception.
The Lyon-based biotech rebounds sharply during the session following a favorable regulatory feedback from the United States on its solid tumor candida…
Following a pre-Investigational New Drug (pre-IND) meeting, MaaT Pharma indicated on October 19, 2026 that the U.S. health authority does not anticipa…
Lyon-based biotech MaaT Pharma published its first-half 2026 results on September 29, 2026, marked by a cash position of €17.1M as of June 30 and a fi…
The Lyon-based biotech company stands out on Tuesday as the strongest performer among all securities listed in Paris, driven by regulatory development…
The Lyon-based biotech company has detailed the next regulatory and clinical steps for MaaT034, its drug candidate intended for advanced solid tumors.…
Following the negative opinion from the CHMP on its graft-versus-host disease treatment, the Lyon-based biotech is concentrating its development effor…
The Lyon-based biotech company has been informed of a negative voting trend from the European Committee for Medicinal Products for Human Use regarding…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Thursday regarding the conditi…
The stock of the Lyon-based biotech company plunges during the session, after a brief rebound on Friday. The stock is now trading at its lowest, as th…
However, the stock remains significantly distant from its pre-CHMP adverse signal levels, and the formal vote of the European committee remains the ce…
